2019
Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west
Lu J, Zhang XP, Zhong BY, Lau WY, Madoff DC, Davidson JC, Qi X, Cheng SQ, Teng GJ. Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west. The Lancet Gastroenterology & Hepatology 2019, 4: 721-730. PMID: 31387735, DOI: 10.1016/s2468-1253(19)30178-5.Peer-Reviewed Original ResearchMeSH KeywordsAnilidesAntibodies, Monoclonal, HumanizedAntineoplastic AgentsCarcinoma, HepatocellularChemoembolization, TherapeuticEndovascular ProceduresHepatectomyHepatic ArteryHumansInfusions, Intra-ArterialLiver NeoplasmsLiver TransplantationNivolumabPatient Care TeamPhenylurea CompoundsPortal VeinPyridinesQuinolinesRadiotherapy, AdjuvantSorafenibStentsVenous ThrombosisConceptsPortal vein tumor thrombosisTumor thrombosisHepatocellular carcinomaOptimise treatment strategiesTranscatheter arterial therapyAdvanced hepatocellular carcinomaManagement of patientsArterial therapySurgical treatmentTreatment strategiesPhysician preferenceNovel treatmentsCarcinomaThrombosisMultidisciplinary teamPatientsReimbursement schemesTreatmentRevascularisationComorbiditiesManagementPrognosisRadiotherapyActive managementTherapy
2011
Development of a Large Animal Model of Cirrhosis and Portal Hypertension Using Hepatic Transarterial Embolization: A Study in Swine
Avritscher R, Wright KC, Javadi S, Uthamanthil R, Gupta S, Gagea M, Bassett RL, Murthy R, Wallace MJ, Madoff DC. Development of a Large Animal Model of Cirrhosis and Portal Hypertension Using Hepatic Transarterial Embolization: A Study in Swine. Journal Of Vascular And Interventional Radiology 2011, 22: 1329-1334. PMID: 21802316, DOI: 10.1016/j.jvir.2011.04.016.Peer-Reviewed Original ResearchPhase I Trial of Hepatic Arterial Infusion of Nanoparticle Albumin–Bound Paclitaxel: Toxicity, Pharmacokinetics, and Activity
Fu S, Naing A, Moulder SL, Culotta KS, Madoff DC, Ng CS, Madden TL, Falchook GS, Hong DS, Kurzrock R. Phase I Trial of Hepatic Arterial Infusion of Nanoparticle Albumin–Bound Paclitaxel: Toxicity, Pharmacokinetics, and Activity. Molecular Cancer Therapeutics 2011, 10: 1300-1307. PMID: 21571911, DOI: 10.1158/1535-7163.mct-11-0259.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAlbuminsAntineoplastic AgentsFemaleHumansInfusions, Intra-ArterialLiver NeoplasmsMaleMiddle AgedPaclitaxelRadiographyTreatment OutcomeConceptsHepatic arterial infusionNab-paclitaxelHepatic extractionArterial infusionDose levelsNanoparticle Albumin-Bound PaclitaxelFirst-pass hepatic extractionPredominant liver metastasesCommon adverse eventsAdvanced cancer patientsAlbumin-Bound PaclitaxelDose-limiting toxicityPeak concentrationHighest dose levelStable diseaseAdverse eventsLiver involvementLiver metastasesPartial responseI trialComparative pharmacokinetic studyHepatic metastasesPoor outcomeCancer patientsNanoparticle albumin
2010
Exploratory Study of Hepatic Arterial Infusion Oxaliplatin With Systemic 5-Fluorouracil/Bevacizumab in Patients With Refractory Solid Tumor and Extensive Liver Metastases
Camacho LH, Garcia S, Panchal AM, Lim J, Hong DS, Ng C, Madoff DC, Fu S, Gayed I, Kurzrock R. Exploratory Study of Hepatic Arterial Infusion Oxaliplatin With Systemic 5-Fluorouracil/Bevacizumab in Patients With Refractory Solid Tumor and Extensive Liver Metastases. Clinical Colorectal Cancer 2010, 9: 311-314. PMID: 21208846, PMCID: PMC3088086, DOI: 10.3816/ccc.2010.n.045.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabColorectal NeoplasmsDrug Resistance, NeoplasmFemaleFluorouracilHepatic ArteryHumansInfusions, Intra-ArterialLeucovorinLiver NeoplasmsMaleMiddle AgedOrganoplatinum CompoundsOvarian NeoplasmsOxaliplatinPilot ProjectsSalvage TherapySurvival RateTomography, X-Ray ComputedTreatment OutcomeConceptsExtensive liver metastasesRefractory solid tumorsLiver metastasesTotal bilirubinSolid tumorsBaseline serum total bilirubinHepatic arterial infusion (HAI) oxaliplatinMedian Child-Pugh scoreAdvanced refractory malignanciesGrade 1 fatigueMedian total bilirubinRegional hepatic therapySystemic anticancer agentsChild-Pugh scoreCommon side effectsSerum total bilirubinPilot clinical trialElevated bilirubinLiver involvementPartial responseHepatic insufficiencyMedian ageRefractory malignanciesClinical trialsDisease progression
2007
Pilot study of regional, hepatic intra‐arterial paclitaxel in patients with breast carcinoma metastatic to the liver
Camacho LH, Kurzrock R, Cheung A, Barber DF, Gupta S, Madoff DC, Wallace MJ, Kim EE, Curley SA, Hortobagyi GN, Mavligit G. Pilot study of regional, hepatic intra‐arterial paclitaxel in patients with breast carcinoma metastatic to the liver. Cancer 2007, 109: 2190-2196. PMID: 17464952, DOI: 10.1002/cncr.22672.Peer-Reviewed Original ResearchConceptsDominant liver metastasisBreast carcinomaTaxane exposureLiver metastasesAntitumor activityCommon treatment-related toxicitiesHepatic intra-arterial therapyPatient underwent liver resectionCourses of paclitaxelUnderwent liver resectionMean patient ageTreatment-related toxicityHepatic arterial infusionIntra-arterial therapyProcedure-related complicationsBreast carcinoma metastaticMetastatic breast carcinomaIntra-arterial catheterPercutaneous transfemoral approachTime of treatmentHepatic infusionStable diseaseCarcinoma metastaticPaclitaxel therapyTaxane therapy